Clinical trials: Aerosol Therapy
Respiratory Insufficiency
RCT of Mesh Versus Jet Nebulizers on Clinical Outcomes During Mechanical Ventilation in the Intensive Care Unit
Aerosol delivery during mechanical ventilation has long been a long debated topic. As evidence-based knowledge about the delivery of aerosol to the lungs of mechanically ventilated patients increases, one piece of the puzzle has…
- Trial name
- NCT02056119
- Testing
- Vibrating Mesh Nebulizer Arm, Jet Nebulizer Arm
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Rush University Medical Center
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This is a Phase IIb, randomized, double blind, chronic dosing (28 days), four period, five treatment, incomplete block, crossover design in subjects with moderate to severe COPD.
- Trial name
- PT009001 (NCT02196077)
- Testing
- BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, BFF MDI 80/9.6 μg
- Where
- 17 sites in United States
- Volunteers
- 180 people
- Sponsor
- Pearl Therapeutics, Inc.
Psoriasis Vulgaris
Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris
To gather insight on how product attributes affect usability by investigating the factors that are thought to influence patient preference to topical anti-psoriatic treatments.
- Trial name
- NCT02310646
- Testing
- LEO 90100 Aerosol Foam, Daivobet® gel
- Where
- Canada
- Volunteers
- 219 people
- Sponsor
- LEO Pharma
Allergic Rhinitis, Perennial Allergic Rhinitis
A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older
This is a 6-month multi-center, randomized, double-blind, placebo-controlled, parallel group, efficacy and safety study of ciclesonide HFA nasal aerosol administered once-daily to male and female subjects 12 years or older…
- Trial name
- NCT00953147
- Testing
- Ciclesonide HFA 80 mcg, Ciclesonide HFA 160 mcg
- Where
- 45 sites in United States
- Volunteers
- 1,110 people
- Sponsor
- Sumitomo Pharma America, Inc.
Lung Cancer
Budesonide in Treating Patients With Lung Nodules at High Risk of Developing Lung Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of budesonide may keep lung cancer from forming in patients with lung nodules.
- Trial name
- NCT00321893
- Testing
- Budesonide
- Where
- Italy
- Volunteers
- 225 people
- Sponsor
- National Cancer Institute (NCI)